InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
58,598.82
(
1.22%
)
Post# of 252588
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: keitern post# 52052

Saturday, 09/08/2007 1:02:43 PM

Saturday, September 08, 2007 1:02:43 PM

Post# of 252588
There’s an array of biotechs selling for cash value or less, but most are broken companies with little chance to recover before the cash runs out. (There’s an SI message board on this topic at http://siliconinvestor.advfn.com/subject.aspx?subjectid=52724 .)

Among companies trading at cash value or less, IDIX is unique in having both an approved drug and a rock-solid balance sheet.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up